About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., founded in 2010, has rapidly established itself as a leader in rare disease drug development with a mission to bring novel therapies to patients with serious genetic diseases. The company's name reflects its focus on ultra-rare conditions where patients often have no treatment options. RARE stock price reflects the company's successful track record of bringing multiple products to market and its continued pipeline advancement.

Led by founder and CEO Emil Kakkis, MD, PhD, who previously founded and led another successful rare disease company, Ultragenyx benefits from visionary leadership with deep expertise in rare disease drug development. The management team combines scientific excellence with proven commercial execution capabilities, having successfully launched multiple products globally. Leadership's strategic focus on building a sustainable rare disease company with diversified revenue streams has been instrumental in creating shareholder value and driving RARE stock price appreciation.

Ultragenyx operates as a fully integrated biopharmaceutical company with approved products generating revenue while continuing to invest in pipeline expansion. The company's commercial portfolio includes treatments for rare metabolic, bone, and genetic diseases, with additional programs in clinical development. With proven ability to develop and commercialize rare disease therapies, multiple revenue-generating products providing financial sustainability, and a robust pipeline offering continued growth potential, RARE represents an attractive investment in the high-value rare disease sector where successful treatments command premium pricing and benefit from market exclusivity.